Context Therapeutics Sets Up Phase 1b With Ovarian Cancer Antibody Data and $34.4m in Cash

Context Therapeutics has paired its third-quarter results with an updated early-stage dataset for CTIM-76, a bispecific antibody that directs T cells to tumours expressing Claudin 6. The data, released on 10 November 2026, come from patients with platinum-resistant ovarian cancer who had already received heavy prior treatment.

In cohorts receiving weekly dosing at active levels, the company reported a confirmed objective response rate of 22% and median progression-free survival of 5.6 months. The figures come from the company; the facts provided do not specify patient numbers or how the cohorts were pooled, so the strength of the signal cannot be judged from this release alone.

Safety is the more nuanced part of the picture. Cytokine release syndrome, a common concern with T cell-engaging drugs, did not exceed Grade 2. Liver enzyme elevations of Grade 3 or higher, however, rose with dose. Context is now escalating a dosing schedule given once every three weeks, and has reached 420 µg. How that schedule balances efficacy against liver effects is likely to inform the dose chosen for later work.

On the regulatory and financial side, the US Food and Drug Administration has awarded CTIM-76 Fast Track designation, a status meant to speed development of drugs for serious conditions with unmet need. Context plans to start a Phase 1b study in the first quarter of 2027. It reported cash of $34.4 million, which it expects to fund operations until early in the fourth quarter of 2027, so the trial would begin with roughly three quarters of runway remaining.